All Fields
Computer Science
Medicine
FAQ
Contact
Sign in
ABT-089
Known as:
A-87089.0
, ABT 089
, ABYT 089
Â
Â
National Institutes of Health
Topic mentions per year
Topic mentions per year
1997-2014
0
2
4
6
1997
2014
Related topics
Related topics
1 relation
Broader (1)
pozanicline
Related mentions per year
Related mentions per year
1997-2015
1990
2000
2010
2020
ABT-089
pozanicline
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.
Emre Yildirim
,
D. Alan C. O ’ Connor
,
Thomas J. Gould
Behavioural pharmacology
2015
Nicotine withdrawal produces cognitive deficits that can predict relapse. Amelioration of these cognitive deficits emerges as a…Â
(More)
Is this relevant?
2014
2014
ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Danhui Zhang
,
Tanuja Bordia
,
M S Mcgregor
,
J. Michael McIntosh
,
Michael W. Decker
,
Maryka Quik
Movement disorders : official journal of the…
2014
Levodopa-induced dyskinesias (LIDs) are a serious complication of levodopa therapy for Parkinson's disease for which there is…Â
(More)
Is this relevant?
2011
2011
Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
Timothy E Wilens
,
Laura M. Gault
,
+9 authors
Mario D. Saltarelli
Journal of the American Academy of Child and…
2011
OBJECTIVE To assess the safety and efficacy of ABT-089, a novel α(4)β(2) neuronal nicotinic receptor partial agonist, vs. placebo…Â
(More)
Is this relevant?
2011
2011
Efficacy and safety of the novel α4β2 neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled…
George G Apostol
,
Walid Michel Abi-Saab
,
+7 authors
Mario D. Saltarelli
Psychopharmacology
2011
α4β2 Neuronal nicotinic receptors (NNRs) are implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD…Â
(More)
Is this relevant?
2009
2009
Selectivity of ABT-089 for alpha4beta2* and alpha6beta2* nicotinic acetylcholine receptors in brain.
Michael J. Marks
,
Charles R. Wageman
,
Sharon R. Grady
,
Murali Gopalakrishnan
,
Clark Briggs
Biochemical pharmacology
2009
Numerous pharmaceutical efforts have targeted neuronal nicotinic receptors (nAChRs) for amelioration of cognitive deficits. While…Â
(More)
Is this relevant?
2006
2006
ABT-089, a neuronal nicotinic receptor partial agonist, for the treatment of attention-deficit/hyperactivity disorder in adults: results of a pilot study.
Timothy E Wilens
,
Marleen H Verlinden
,
Lenard A. Adler
,
Patricia J Wozniak
,
Scott A. West
Biological psychiatry
2006
BACKGROUND This pilot study was designed to evaluate ABT-089, a neuronal nicotinic receptor partial agonist, as treatment for…Â
(More)
Is this relevant?
1998
1998
Central nicotinic receptor agonists ABT-418, ABT-089, and (–)-nicotine reduce distractibility in adult monkeys
Mark A. Prendergast
,
William J. Jackson
,
Alvin V. Terry
,
Michael W. Decker
,
Stephen Arneric
,
Jerry J. Buccafusco
Psychopharmacology
1998
 Increased distractibility is associated with both Alzheimer’s disease and attention deficit disorder. The present study examined…Â
(More)
Is this relevant?
1997
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.
J. P. Sullivan
,
D L Donnelly-roberts
,
+15 authors
Stephen Arneric
The Journal of pharmacology and experimental…
1997
Accumulating preclinical and clinical evidence data suggests that compounds that selectively activate neuronal nicotinic…Â
(More)
Is this relevant?
1997
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys.
M. W. Decker
,
Aidan Bannon
,
+10 authors
Stephen Arneric
The Journal of pharmacology and experimental…
1997
ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine dihydrochloride], a novel ligand at neuronal nicotinic acetylcholine…Â
(More)
Is this relevant?
1997
1997
Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing…
Nan-horng Lin
,
David E Gunn
,
+14 authors
Martha Holladay
Journal of medicinal chemistry
1997
2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine, ABT-089 (S-4), a member of the 3-pyridyl ether class of nicotinic acetylcholine…Â
(More)
Is this relevant?